## Respiratory Syncytial Virus (RSV) Vaccine

### Vaccine Description
- **Brands and types**
  - ABRYSVO™: Bivalent, recombinant protein subunit
  - AREXVY™: Adjuvanted, monovalent, recombinant subunit
- Neither vaccine contains preservatives or latex but both may have residual host cell proteins
- See package inserts

### Dose & Route
- **Dose:** 0.5 mL
- **Route:** IM (Use IM precautions for persons with bleeding disorders or receiving anticoagulant therapy)
- See package inserts

### Indications
- Individuals 60 years and older for the prevention of lower respiratory tract disease caused by RSV, using shared clinical decision making

### Administrative Schedule
- One dose

### Booster
- None

### Contraindications
- History of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO™ or AREXVY™

### Precautions
- Vaccination should be delayed for persons experiencing moderate or severe acute illness with or without fever
- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration
- Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
- Vaccines may be less effective in immunocompromised persons, including those receiving immunosuppressive therapy

### Special Considerations
- Discard vaccine if not used within 4 hours of reconstitution
- See package insert for reconstitution instructions for each vaccine
- See Storage and Handling Section

VIS: [https://www.cdc.gov/vaccines/hcp/vis/vis-statements/rsv.html](https://www.cdc.gov/vaccines/hcp/vis/vis-statements/rsv.html)
Additional information may be found at: [www.health.mil/rsv](http://www.health.mil/rsv)